A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth. Trump's comments added pressure to an already sensitive market, raising concerns about political interference in monetary policy.
What a time it’s been for Guardant Health. In the past six months alone, the company’s stock price has increased by a massive 112%, reaching $44.11 per share. This run-up might have investors contemplating their next move.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting with Guardant Health (NASDAQ:GH).
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting with RadNet (NASDAQ:RDNT).
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 8.4%. This drop was disappointing since the S&P 500 stood firm.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst performers in the testing & diagnostics services industry.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.
Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 30.2% year on year to $201.8 million. Its GAAP loss of $0.90 per share was 12.4% below analysts’ consensus estimates.
Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.
Top performers in last week's mid-cap stocks: Oklo Inc., Tempus AI, Himax Tech, Super Group, NuScale Power, WNS Holdings, Guardant Health, Rigetti Computing.
Guardant Reveal test receives expanded Medicare coverage for colorectal cancer recurrence monitoring, enhancing revenue potential and clinical adoption.
